PolyPeptide Group Salute del bilancio

Salute finanziaria criteri di controllo 5/6

PolyPeptide Group ha un patrimonio netto totale di €359.9M e un debito totale di €91.7M, che porta il suo rapporto debito/patrimonio netto a 25.5%. Le sue attività totali e le sue passività totali sono rispettivamente €665.0M e €305.1M.

Informazioni chiave

25.5%

Rapporto debito/patrimonio netto

€91.72m

Debito

Indice di copertura degli interessi	n/a
Contanti	€48.48m
Patrimonio netto	€359.92m
Totale passività	€305.05m
Totale attività	€664.97m

Aggiornamenti recenti sulla salute finanziaria

PolyPeptide Group (VTX:PPGN) Is Making Moderate Use Of Debt

Oct 21

Does PolyPeptide Group (VTX:PPGN) Have A Healthy Balance Sheet?

Jun 19

Recent updates

PolyPeptide Group AG's (VTX:PPGN) Intrinsic Value Is Potentially 19% Below Its Share Price

Nov 11

Further Upside For PolyPeptide Group AG (VTX:PPGN) Shares Could Introduce Price Risks After 33% Bounce

Mar 14

PolyPeptide Group AG's (VTX:PPGN) Intrinsic Value Is Potentially 99% Above Its Share Price

Mar 13

PolyPeptide Group AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 18

Investors Shouldn't Be Too Comfortable With PolyPeptide Group's (VTX:PPGN) Robust Earnings

Mar 23

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( €292.6M ) di PPGN superano le sue passività a breve termine ( €183.6M ).

Passività a lungo termine: Le attività a breve termine di PPGN ( €292.6M ) superano le sue passività a lungo termine ( €121.4M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 12% ) di PPGN è considerato soddisfacente.

Riduzione del debito: Il rapporto debito/patrimonio netto di PPGN si è ridotto da 30.5% a 25.5% negli ultimi 5 anni.

Copertura del debito: Il debito di PPGN è ben coperto dal flusso di cassa operativo ( 93% ).

Copertura degli interessi: Dati insufficienti per determinare se i pagamenti degli interessi sul debito di PPGN siano ben coperti dall'EBIT.

PolyPeptide Group Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

PolyPeptide Group (VTX:PPGN) Is Making Moderate Use Of Debt

Does PolyPeptide Group (VTX:PPGN) Have A Healthy Balance Sheet?

Recent updates

PolyPeptide Group AG's (VTX:PPGN) Intrinsic Value Is Potentially 19% Below Its Share Price

Now 22% overvalued after recent price rise

PolyPeptide Group (VTX:PPGN) Is Making Moderate Use Of Debt

Sentiment Still Eluding PolyPeptide Group AG (VTX:PPGN)

Consensus EPS estimates fall by 16%

Consensus EPS estimates fall by 15%

Does PolyPeptide Group (VTX:PPGN) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 17%, revenue upgraded

Further Upside For PolyPeptide Group AG (VTX:PPGN) Shares Could Introduce Price Risks After 33% Bounce

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

PolyPeptide Group AG's (VTX:PPGN) Intrinsic Value Is Potentially 99% Above Its Share Price

New major risk - Share price stability

PolyPeptide Group AG, Annual General Meeting, Apr 09, 2025

PolyPeptide Group AG to Report First Half, 2025 Results on Aug 12, 2025

First half 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall from profit to €1.13 loss

New major risk - Share price stability

Consensus EPS estimates fall by 24%

Consensus EPS estimates fall by 17%

Consensus EPS estimates fall by 16%

PolyPeptide Group AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 21%

Consensus EPS estimates fall by 19%

PolyPeptide Group AG to Report First Half, 2024 Results on Aug 13, 2024

PolyPeptide Group AG Appoints Peter Wilden as Executive Chairman

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

Consensus forecasts updated

Consensus EPS estimates fall by 13%

Investor sentiment deteriorated over the past week

High number of new and inexperienced directors

Investor sentiment improved over the past week

PolyPeptide Group AG to Report Fiscal Year 2022 Results on Mar 14, 2023

Investor sentiment deteriorated over the past week

First half 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Consensus EPS estimates fall by 11%

PolyPeptide Group AG to Report First Half, 2022 Results on Aug 19, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

High number of new and inexperienced directors

PolyPeptide Group AG Appoints Monika Casanova as Chief Human Resources Officer and Member of its Management Committee

PolyPeptide Group AG Approves Cash Distribution for the Year 2021, Payable on May 02, 2022

PolyPeptide Group AG Proposes Cash Distribution for the Year 2021

Investors Shouldn't Be Too Comfortable With PolyPeptide Group's (VTX:PPGN) Robust Earnings

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorated over the past week

Insufficient new directors

Insufficient new directors

Consensus EPS estimates increase to €1.57

PolyPeptide Group AG has completed an IPO in the amount of CHF 737.39136 million.

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane